Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2025-01-06
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ixazomib citrate and rituximab work in treating patients
with B-cell non-Hodgkin lymphoma that grows slowly (indolent). Ixazomib citrate may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a
monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Giving ixazomib citrate together with rituximab may work better in treating indolent B-cell
non-Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)